GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+64.56%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$403M
AUM Growth
+$403M
(+36%)
Cap. Flow
+$7.45M
Cap. Flow
% of AUM
1.85%
Top 10 Holdings %
Top 10 Hldgs %
52.59%
Holding
59
New
12
Increased
9
Reduced
13
Closed
17
Top Buys
| 1 |
Syndax Pharmaceuticals
SNDX
|
$20.6M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$18.6M |
| 3 |
Travere Therapeutics
TVTX
|
$12.9M |
| 4 |
Cogent Biosciences
COGT
|
$12.4M |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$8.51M |
Top Sells
| 1 |
Mersana Therapeutics
MRSN
|
$12M |
| 2 |
Adverum Biotechnologies
ADVM
|
$12M |
| 3 |
Immunovant
IMVT
|
$10.4M |
| 4 |
Aurinia Pharmaceuticals
AUPH
|
$8.1M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
$7.82M |
Sector Composition
| 1 | Healthcare | 92.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Syndax Pharmaceuticals
SNDX
$1.41B
| $30M | 6.69% | 1,350,000 +925,000 | +218% | +$20.6M |
|
|
TRIL
2
DELISTED
Trillium Therapeutics Inc.
TRIL
| $28.7M | 6.39% | 1,950,000 | – | – |
|
3
Rocket Pharmaceuticals
RCKT
$354M
| $27.4M | 6.11% | 500,000 +100,000 | +25% | +$5.48M |
|
4
Iovance Biotherapeutics
IOVA
$807M
| $23.2M | 5.17% | 500,000 -75,000 | -13% | -$3.48M |
|
|
5
Apellis Pharmaceuticals
APLS
$3.48B
| $18.6M | 4.14% | +325,000 | New | +$18.6M |
|
|
CNST
6
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $18M | 4.01% | 625,000 -100,000 | -14% | -$2.88M |
|
7
Ascendis Pharma
ASND
$11.8B
| $17.5M | 3.9% | 105,000 -25,000 | -19% | -$4.17M |
|
8
Arvinas
ARVN
$568M
| $17.4M | 3.88% | 205,000 +5,000 | +3% | +$425K |
|
|
9
Mersana Therapeutics
MRSN
$36.5M
| $16M | 3.56% | 600,000 -450,000 | -43% | -$12M |
|
10
Fate Therapeutics
FATE
$120M
| $15M | 3.34% | 165,000 -35,000 | -18% | -$3.18M |
|
|
11
Immunovant
IMVT
$2.56B
| $13.9M | 3.09% | 300,000 -225,000 | -43% | -$10.4M |
|
12
Amicus Therapeutics
FOLD
$2.34B
| $13.9M | 3.09% | 600,000 | – | – |
|
13
TG Therapeutics
TGTX
$4.65B
| $13M | 2.9% | 250,000 +50,000 | +25% | +$2.6M |
|
|
14
Travere Therapeutics
TVTX
$1.56B
| $12.9M | 2.88% | +475,000 | New | +$12.9M |
|
|
15
Cogent Biosciences
COGT
$1.69B
| $12.4M | 2.75% | +1,100,000 | New | +$12.4M |
|
|
MRTX
16
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $11M | 2.45% | 50,000 -10,000 | -17% | -$2.2M |
|
17
Xenon Pharmaceuticals
XENE
$2.98B
| $10.8M | 2.4% | 700,000 +375,000 | +115% | +$5.77M |
|
18
Kura Oncology
KURA
$686M
| $10.6M | 2.37% | 325,000 +100,000 | +44% | +$3.27M |
|
|
ISEE
19
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $9.5M | 2.12% | 1,375,000 +375,000 | +38% | +$2.59M |
|
|
SURF
20
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $9.24M | 2.06% | 1,000,000 | – | – |
|
|
FPRX
21
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $8.51M | 1.9% | +500,000 | New | +$8.51M |
|
22
Sarepta Therapeutics
SRPT
$1.78B
| $6.82M | 1.52% | 40,000 -25,000 | -38% | -$4.26M |
|
|
23
BioCryst Pharmaceuticals
BCRX
$1.74B
| $6.71M | 1.49% | 900,000 -1,050,000 | -54% | -$7.82M |
|
24
MoonLake Immunotherapeutics
MLTX
$3.54B
| $5.69M | 1.27% | +500,000 | New | +$5.69M |
|
|
VRNA
25
Verona Pharma
VRNA
$9.16B
| $5.67M | 1.26% | 810,000 +4,444 | +0.6% | +$31.1K |
|